Enhanced prognostic value of four‐tier hybrid grading system in Ta non‐muscle‐invasive bladder cancer
BJU International · 2025-11 · 136 (5) · 882-890
DOI: 10.1111/bju.16828 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 25.06.2025. Verfasst von Matteo Ferro und 59 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Urology, Department of Health Science, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Neoplasm Grading. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Objectives
To compare the predictive performance of the World Health Organization (WHO) 1973, WHO 2004/2022, the three‐tier (low grade [LG]/Grade 1 [G1]–G2, high grade [HG]/G2, and HG/G3), and four‐tier (LG/G1, LG/G2, HG/G2, and HG/G3) hybrid grading systems in Ta non‐muscle‐invasive bladder cancer (NMIBC), by evaluating recurrence‐free survival (RFS) and progression‐free survival (PFS). Patients and Methods This retrospective multicentre study included 1233 patients with pTa NMIBC treated with transurethral resection of bladder tumour, eventually followed by intravesical instillations as determined by their physicians, between 2010 and 2023, across 18 Italian hospitals. Pathologists graded resected tissues using the WHO 1973, WHO 2004/2022 classifications, and hybrid three‐tier (LG, HG/G2, HG/G3) and four‐tier (LG/G1, LG/G2, HG/G2, HG/G3) systems. Kaplan–Meier curves estimated RFS and PFS. Discriminative performance was assessed using Harrell's concordance index (C‐index).
Results
Among 1233 patients with pTa NMIBC, 890 were classified as LG and 343 as HG according to the WHO 2004/2022 grading system, while 586, 405, and 242 were categorised as G1, G2, and G3, respectively, under the WHO 1973 system. With a median (interquartile range) follow‐up of 26 (14–48) months, 418 patients experienced recurrence, including 184 with HG recurrence and 42 who progressed to MIBC. The C‐index values for RFS were 0.60, 0.56, 0.57, and 0.61 for the WHO 1973, WHO 2004/2022, hybrid three‐tier, and four‐tier grading systems, respectively. For progression, the C‐index values were 0.80, 0.74, 0.75, and 0.81 across the same systems, underscoring the superior predictive capacity of the four‐tier classification. Nonetheless, the low number of MIBC progression events limits the robustness of these analyses.
Conclusion
Our findings highlight the superior prognostic accuracy of the four‐tier hybrid classification in predicting recurrence and progression in patients with stage Ta NMIBC. By combining strengths from the WHO 1973 and 2004/2022, this hybrid model shows promise as tool for enhancing NMIBC patient management in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Urology, Department of Health Science, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy.
- Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
- School of Medicine, University of Milano-Bicocca, Milan, Italy.
- Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy.
ORCID-Profile: Matteo Ferro, Roberto Bianchi, Marco Tozzi, Francesco Chierigo, Alessandro Uleri, Ludovica Cella, Enrico Checcucci, Francesca Vedovo, Beat Roth, Riccardo Mastroianni, Giuseppe Lucarelli, Arturo Lo Giudice, Francesco Pio Bizzarri, Alessandro Crestani, Francesco Claps, Fabio Zattoni, Cosimo De Nunzio, Francesco Porpiglia, Bernardo Rocco, Biagio Barone
Zitieren
APA
Ferro, M., Catellani, M., Bianchi, R., Fallara, G., Tozzi, M., Maggi, M., Chierigo, F., Uleri, A., Da Pozzo, L. F., Cella, L., Hurle, R., Di Stasi, M. S., Checcucci, E., Bove, P., Maiorino, F., Vartolomei, M. D., Montanari, E., Albo, G., De Lorenzis, E., …, & Contieri, R. (2025). Enhanced prognostic value of four‐tier hybrid grading system in Ta non‐muscle‐invasive bladder cancer. BJU International, 136(5), 882-890. https://doi.org/10.1111/bju.16828
Vancouver
Ferro M, Catellani M, Bianchi R, Fallara G, Tozzi M, Maggi M, et al. Enhanced prognostic value of four‐tier hybrid grading system in Ta non‐muscle‐invasive bladder cancer. BJU International. 2025;136(5):882-890. doi:10.1111/bju.16828
BibTeX
@article{Ferro2025,
author = {Ferro, Matteo and Catellani, Michele and Bianchi, Roberto and Fallara, Giuseppe and Tozzi, Marco and Maggi, Martina and Chierigo, Francesco and Uleri, Alessandro and Da Pozzo, Luigi Filippo and Cella, Ludovica and Hurle, Rodolfo and Di Stasi, Mauro Savino and Checcucci, Enrico and Bove, Pierluigi and Maiorino, Francesco and Vartolomei, Mihai Dorin and Montanari, Emanuele and Albo, Giancarlo and De Lorenzis, Elisa and Boeri, Luca and Liguori, Giovanni and Vedovo, Francesca and Roth, Beat and Busetto, Gian Maria and Falagario, Ugo and Mastroianni, Riccardo and Madonia, Massimo and Tedde, Alessandro and Di Tonno, Pasquale and Lucarelli, Giuseppe and Forte, Saverio and Russo, Giorgio Ivan and Lo Giudice, Arturo and Verweij, Fabrizio and Racioppi, Marco and Bizzarri, Francesco Pio and Crestani, Alessandro and Rinaldi, Marco and Cerruto, Maria Angela and Claps, Francesco and Conti, Andrea and Perdonà, Sisto and Dal Moro, Fabrizio and Zattoni, Fabio and Imbimbo, Ciro and Crocetto, Felice and Aveta, Achille and Pandolfo, Savio Domenico and Porreca, Angelo and Carrieri, Giuseppe and Carmignani, Luca and De Nunzio, Cosimo and Simone, Giuseppe and Cormio, Luigi and Borghesi, Marco and Antonelli, Alessandro and Porpiglia, Francesco and Rocco, Bernardo and Barone, Biagio and Contieri, Roberto},
title = {Enhanced prognostic value of four‐tier hybrid grading system in Ta non‐muscle‐invasive bladder cancer},
journal = {BJU International},
year = {2025},
volume = {136},
number = {5},
pages = {882--890},
doi = {10.1111/bju.16828}
}
EUVIMED